Efficient stimulation of T cell responses by human IFN-α-induced dendritic cells does not require toll-like receptor triggering

Journal of Immunotherapy

Volumn 31, Issue 5, 2008, Pages 466-474

  Bracci, Laura ^a,b   Schumacher, Reto ^a   Provenzano, Maurizio ^a   Adamina, Michel ^a   Rosenthal, Rachel ^a   Groeper, Celia ^a   Zajac, Paul ^a   Iezzi, Giandomenica ^a   Proietti, Enrico ^b   Belardelli, Filippo ^b   Spagnoli, Giulio C ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Dendritic cells; Imidazoquinolone; Interferons; T cell response; Toll like receptors

Indexed keywords

ALPHA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIDAZOQUINOLONE; INTERLEUKIN 12; INTERLEUKIN 6; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; INTERLEUKIN 4;

ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; DRUG EFFECT; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM;

CELL DIFFERENTIATION; CELLS, CULTURED; DENDRITIC CELLS; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; PHENOTYPE; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS;

EID: 52949125383     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318174a52a     Document Type: Article

References (41)

1. Guermonprez P, Valladeau J, Zitvogel L, et al. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002; 20:621-667.
2. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5:296-306.
3. Gilboa E. DC-based cancer vaccines. J Clin Invest. 2007;117: 1195-1203.
4. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994; 179:1109-1118.
5. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol. 2003;15:138-147.
6. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252.
7. + T cell populations lacking helper function. Nat Immunol. 2005;6: 163-170.
8. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol. 2004;5:987-995.
9. Langenkamp A, Messi M, Lanzavecchia A, et al. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol. 2000;1:311-316.
10. Aguilar JC, Rodriguez EG. Vaccine adjuvants revisited. Vaccine. 2007;25:3752-3762.
11. Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999;284:1835-1837.
12. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol. 2004;5:1219-1226.
13. Montoya M, Schiavoni G, Mattei F, et al. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood. 2002;99:3263-3271.
14. Luft T, Pang KC, Thomas E, et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol. 1998;161: 1947-1953.
15. Santini SM, Lapenta C, Logozzi M, et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med. 2000; 191:1777-1788.
16. + effector T cells. J Leukoc Biol. 2002;71:669-676.
17. + T cell response. J Immunol. 2003;170:5195-5202.
18. Lapenta C, Santini SM, Spada M, et al. IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. Eur J Immunol. 2006;36: 2046-2060.
19. Parlato S, Santini SM, Lapenta C, et al. Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood. 2001;98: 3022-3029.
20. Mohty M, Vialle-Castellano A, Nunes JA, et al. IFN-alpha skews monocyte differentiation into toll-like receptor 7-expressing dendritic cells with potent functional activities. J Immunol. 2003;171: 3385-3393.
21. Shackleton M, Davis ID, Hopkins W, et al. The impact of imiquimod, a toll-like receptor-7 ligand (TLR7L), on the immuno-genicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun. 2004;4:9.
22. Stockfleth E, Trefzer U, Garcia-Bartels C, et al. The use of toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol. 2003;149(suppl 66):53-56.
23. Huang LQ, Brasseur F, Serrano A, et al. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma. J Immunol. 1999;162:6849-6854.
24. Graff-Dubois S, Faure O, Gross DA, et al. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J Immunol. 2002;169: 575-580.
25. Gure AO, Stockert E, Arden KC, et al. CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis. Int J Cancer. 2000;85: 726-732.
26. Feder-Mengus C, Ghosh S, Weber WP, et al. Multiple mechanisms underlie defective recognition of melanoma cells cultured in three-dimensional architectures by antigen-specific cytotoxic T lymphocytes. Br J Cancer. 2007;96:1072-1082.
27. Wilusz CJ, Wormington M, Peltz SW. The cap-to-tail guide to mRNA turnover. Nat Rev Mol Cell Biol. 2001;2:237-246.
28. Dunbar PR, Smith CL, Chao D, et al. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J Immunol. 2000;165:6644-6652.
29. Hengge UR, Ruzicka T. Topical immunomodulation in dermatology: potential of toll-like receptor agonists. Dermatol Surg. 2004; 30:1101-1112.
30. Urosevic M, Dummer R. Role of imiquimod in skin cancer treatment. Am J Clin Dermatol. 2004;5:453-458.
31. Groeper C, Gambazzi F, Zajac P, et al. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. Int J Cancer. 2007;120:337-343.
32. + T-helper and a T-killer cell. Nature. 1998;393:474-478.
33. Lanzavecchia A, Sallusto F. The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics. Curr Opin Immunol. 2001;13:291-298.
34. Diebold SS, Kaisho T, Hemmi H, et al. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004;303:1529-1531.
35. Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity. 2006;25:373-381.
36. Gavin AL, Hoebe K, Duong B, et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science. 2006; 314:1936-1938.
37. + T cells induced by TCR triggering or homeostatic cytokines. Eur J Immunol. 2006;36: 296-304.
38. Munn DH. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol. 2006;18:220-225.
39. Schwarz K, Storni T, Manolova V, et al. Role of toll-like receptors in costimulating cytotoxic T cell responses. Eur J Immunol. 2003;33: 1465-1470.
40. Wu X, Peng SL. Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheum. 2006;54:336-342.
41. Camporeale A, Boni A, Iezzi G, et al. Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes. Cancer Res. 2003;63:3688-3694.